SCHEMBL13289036

SCHEMBL13289036

Bc1cnn2c(NCCCN(C)C(=O)c3cccc(C#N)c3)cc(-c3ccccc3Cl)nc12

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.40
▸ GSK3B P49841 6/20 0.39
▸ CDK2 P24941 3/20 0.39
▸ ADORA2A P29274 3/20 0.37
▸ VNN1 O95497 1/20 0.37
▸ CSNK2A1 P68400 1/20 0.36
▸ HIPK2 Q9H2X6 1/20 0.36
▸ BRD4 O60885 1/20 0.36
▸ KDM4E B2RXH2 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ MAPK1 P28482 2/20 0.35
▸ NPSR1 Q6W5P4 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ GFER P55789 1/20 0.35
▸ KCNA3 P22001 1/20 0.35
▸ CCR6 P51684 1/20 0.34
▸ GRM5 P41594 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14418781 0.92 ADORA2A (0.38) GSK3BADORA2ACSNK2A1HIPK2BRD4
SCHEMBL13120400 0.91 GSK3B (0.51) ALDH1A1GSK3BCDK2ADORA2AVNN1
SCHEMBL13289312 0.90 CDK2 (0.37) ALDH1A1GSK3BCDK2CSNK2A1HIPK2
SCHEMBL13288966 0.89 GSK3B (0.40) GSK3BCDK2BRD4KDM4EMAPT
SCHEMBL13288863 0.88 CSNK2A1 (0.39) ALDH1A1GSK3BCDK2CSNK2A1HIPK2
SCHEMBL13289307 0.88 GSK3B (0.41) GSK3BCDK2CSNK2A1HIPK2BRD4
SCHEMBL13288758 0.88 KDM4E (0.42) ALDH1A1GSK3BCDK2BRD4KDM4E
SCHEMBL13288834 0.88 GSK3B (0.42) ALDH1A1GSK3BCDK2CSNK2A1HIPK2
SCHEMBL13288925 0.87 CDK2 (0.39) GSK3BCDK2KDM4EMAPTMAPK1
SCHEMBL13288912 0.86 GSK3B (0.43) ALDH1A1GSK3BCDK2CSNK2A1HIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2194058-A1 Pyrazolopyrimidines suitable for the treatment of cancer diseases SCHERING CORPORATION (US) 2010-06-09 — — EP disclosed
Send feedback